These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. Mehran R; Pocock S; Nikolsky E; Dangas GD; Clayton T; Claessen BE; Caixeta A; Feit F; Manoukian SV; White H; Bertrand M; Ohman EM; Parise H; Lansky AJ; Lincoff AM; Stone GW JACC Cardiovasc Interv; 2011 Jun; 4(6):654-64. PubMed ID: 21700252 [TBL] [Abstract][Full Text] [Related]
9. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials. Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052 [TBL] [Abstract][Full Text] [Related]
10. Bivalirudin started during emergency transport for primary PCI. Steg PG; van 't Hof A; Hamm CW; Clemmensen P; Lapostolle F; Coste P; Ten Berg J; Van Grunsven P; Eggink GJ; Nibbe L; Zeymer U; Campo dell' Orto M; Nef H; Steinmetz J; Soulat L; Huber K; Deliargyris EN; Bernstein D; Schuette D; Prats J; Clayton T; Pocock S; Hamon M; Goldstein P; N Engl J Med; 2013 Dec; 369(23):2207-17. PubMed ID: 24171490 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655 [TBL] [Abstract][Full Text] [Related]
12. Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy. Sardi GL; Lindsay J; Waksman R Catheter Cardiovasc Interv; 2013 Oct; 82(4):614-20. PubMed ID: 22581418 [TBL] [Abstract][Full Text] [Related]
13. Bleeding complications with regional adaptation of a prolonged bivalirudin regimen for ST-elevation acute myocardial infarction. Mueller E; Prabhu W; Desarno M; Sundaran P; Dauerman H Am J Cardiol; 2012 Dec; 110(11):1607-12. PubMed ID: 22901969 [TBL] [Abstract][Full Text] [Related]
14. Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial. Sanborn TA; Tomey MI; Mehran R; Généreux P; Witzenbichler B; Brener SJ; Kirtane AJ; McAndrew TC; Kornowski R; Dudek D; Nikolsky E; Stone GW Catheter Cardiovasc Interv; 2015 Feb; 85(3):371-9. PubMed ID: 25179260 [TBL] [Abstract][Full Text] [Related]
15. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital. Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538 [TBL] [Abstract][Full Text] [Related]
16. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942 [TBL] [Abstract][Full Text] [Related]
17. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy. Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175 [TBL] [Abstract][Full Text] [Related]
18. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). Ng VG; Baumbach A; Grinfeld L; Lincoff AM; Mehran R; Stone GW; Lansky AJ Am J Cardiol; 2016 Jan; 117(2):186-91. PubMed ID: 26704028 [TBL] [Abstract][Full Text] [Related]
19. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). Stone GW; Clayton T; Deliargyris EN; Prats J; Mehran R; Pocock SJ J Am Coll Cardiol; 2014 Jan 7-14; 63(1):15-20. PubMed ID: 24140664 [TBL] [Abstract][Full Text] [Related]
20. The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial. Liang Z; Li Y; Wang J; Wang D; Wang S; Ma L; Liu H; Yang L; Stone GW; Han Y Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():608-15. PubMed ID: 26762481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]